Why Enliven Therapeutics, Inc.’s (ELVN) Stock Is Down 7.94%
As of Tuesday, October 06, Enliven Therapeutics, Inc.’s ELVN share price has dipped by 7.94%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Commentary & Analysis
Why Enliven Therapeutics, Inc.’s (ELVN) Stock Is Down 5.02%
As of Wednesday, August 05, Enliven Therapeutics, Inc.’s ELVN share price has dipped by 5.02%, which has investors questioning if this is right time to buy.Michael Rose
Why Enliven Therapeutics, Inc.’s (ELVN) Stock Is Up 5.13%
As of Tuesday, June 23, Enliven Therapeutics, Inc.’s ELVN share price has surged by 5.13%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Enliven Therapeutics, Inc.’s (ELVN) Stock Is Up 5.50%
As of Monday, June 22, Enliven Therapeutics, Inc.’s ELVN share price has surged by 5.50%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Enliven Therapeutics, Inc.’s (ELVN) Stock Is Up 6.28%
As of Wednesday, May 13, Enliven Therapeutics, Inc.’s ELVN share price has surged by 6.28%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ELVN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,881.7 | $476.1 | 60% |
|
| Shares Out (Mil) | 66.2 | 42.8 | 54% |
|
| Institutional Ownership | 97.3% | 81.7% | 73% |
|
| Float (Mil) | 60.5 | 44.5 | 51% |
|
| Beta | 0.24 | 0.71 | 14% |
|
| Avg Daily Volume (000s) | 1,309 | 366 | 75% |
|
| Price Change (52-week) |
95.7% | 55.9% | 94% |
|
| Growth | ELVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (40.4%) | (2.0%) | 9% |
|
| EPS (5yr) | 13.6% | 15.0% | 53 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.1%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.458) | ($1.939) | ($2.354) | |
| Month Ago EPS | ($0.448) | ($1.846) | ($2.338) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.433) | ($1.695) | ($2.325) | |
| Year/Year Chg | (6.7%) | 6.0% | 68.1% | |
| Financials | ELVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($106) | ($11) | 11% |
|
| EPS (TTM) | ($1.672) | ($0.700) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($67) | ($7) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $16 | $5 | 60% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 16% |
|
| Enterprise Value (Q1) (Mil) | $3,536 | $494 | 57% |
|
| Valuation | ELVN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.22 | 2.19 | 70% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ELVN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (15.0%) | (22.2%) | 22% |
|
| ROE | (15.3%) | (21.4%) | 25% |
|
| Liabilities to Assets | 1.7% | 32.8% | 1% |
|
| F-Score | 3 | 3 | 18% |
|
Enliven Therapeutics, Inc. did not pass any screens on 10/15/2026.
